Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF
Abstract Introduction To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high-income countries using ranibizumab or aflibercept as initial treatments. Meth...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Adis, Springer Healthcare
2025-06-01
|
| Serier: | Ophthalmology and Therapy |
| Fag: | |
| Online adgang: | https://doi.org/10.1007/s40123-025-01178-z |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
